Health Care·Pharmaceuticals·$49.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.15 | N/A | +0.44% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.15 | N/A | +0.44% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed confidence in the company's long-term growth strategy. They emphasized their commitment to innovation and market expansion.
The company remains focused on innovation and expanding its product offerings.
Management highlighted the resilience of the veterinary market despite economic challenges.
Zoetis reported a positive surprise in EPS, which contributed to a strong stock reaction, rising by 5.37%. The company remains focused on innovation and growth in the veterinary market, which may help sustain investor confidence moving forward. However, the lack of revenue data and forward guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FIRSTENERGY CORP
Feb 13, 2023